Literature DB >> 9248976

Respiratory tract infection: epidemiology and surveillance.

M R Jacobs1.   

Abstract

Streptococcus pneumoniae and Haemophilus influenzae are the key pathogens implicated in bacterial infections of the upper and lower respiratory tract. Choice of empiric oral antimicrobial chemotherapy is guided by the clinical presentation, severity of the infection and epidemiological knowledge. beta-Lactams and the macrolides are the two major groups of antibiotics used to treat respiratory tract infections. The prevalence of penicillin-resistant strains of S. pneumoniae is increasing world-wide (up to 30% in the USA), as is the prevalence of beta-lactamase-producing strains of H. influenzae. Macrolide resistance in S. pneumoniae is increasing and is absolute, and some of the macrolides have only limited activity against H. influenzae. Knowledge of local and global antibiotic resistance patterns should be used as the key to directing empiric choice of antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248976

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

1.  Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  V Berry; C E Thorburn; S J Knott; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.

Authors:  C E Thorburn; S J Knott; D I Edwards
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

3.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

4.  National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.

Authors:  Ian A Critchley; Steven D Brown; Maria M Traczewski; Glenn S Tillotson; Nebojsa Janjic
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

5.  Optimizing economic outcomes in acute exacerbations of chronic bronchitis.

Authors:  Christopher J Destache
Journal:  Pharmacotherapy       Date:  2002-01       Impact factor: 4.705

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.